Managing toxicities associated with immunotherapy in multiple myeloma

Surbhi Sidana, MD, Stanford University, Stanford, CA, explores strategies for mitigating immunotherapy-related toxicities in multiple myeloma (MM). She emphasizes effective prophylaxis for cytopenias and infections, advocating the use of intravenous immunoglobulin (IVIg) and steroids, along with growth factors, to manage neutropenia. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.